Intelligent Bio Solutions Inc. - Common Stock INBS 深 滬
已收盤 09-26 16:00:00 美东时间
1.12
-0.160
-12.50%
華盛通- 最 高1.21
- 今 開1.19
- 成交量 88.54万股
- 最 低 1.08
- 昨 收 1.28
- 總市值 978.25万
- 52周最高 2.75
- 市盈率 靜 --
- 換手率 10.14%
- 52周最低 1.08
- 委 比 32.25%
- 總股本 873.44万
- 歷史最高 3417.60
- 量 比 4.47
- 振 幅 10.16%
- 歷史最低 1.08
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Intelligent Bio Solutions Initiates Clinical Studies For Fingerprint Drug Screening System; Targets FDA 510(k) Clearance In H2 2026 For Codeine Detection
The Company is initiating clinical studies to further validate Intelligent Fingerprinting Drug Screening SystemINBS anticipates FDA 510(k) clearance in the second half of 2026
09-26 20:37
Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance
<p>Intelligent Bio Solutions Inc. (INBS) plans to initiate clinical studies for its Intelligent Fingerprinting Drug Screening System by the end of 2025, aiming to obtain FDA 510(k) clearance by the second half of 2026. The company has outlined a timeline to strengthen its submission with additional data. Currently, the technology is used by over 450 accounts in 24 countries and continues to expand globally.</p>
09-26 12:30
Intelligent Bio Solutions Extends Warrant Termination Date
The latest announcement is out from Intelligent Bio Solutions ( ($INBS) ). On S...
09-26 05:30
Intelligent Bio Solutions Receives FDA Feedback, Preparing To Resubmit 510(k) For Intelligent Fingerprinting Drug Screening System
Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today provided an update on its FDA 510(k) clearance
09-17 20:34
Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July
Intelligent Bio Solutions Inc. (INBS) reported record cartridge sales in July 2025, with 519 boxes shipped, representing over 12,500 cartridges and a 60% year-on-year increase. This growth reflects the strength of the company's razor/razor blade business model, driven by new contracts and expanding global installed base. A major transportation sector tender win and increased demand for consumables contributed to the surge. CEO Harry Simeonidis hi...
08-19 12:30
Intelligent Bio Solutions Q4 EPS $(0.36), Sales $843.884K Up From $727.824K YoY
Intelligent Bio Solutions (NASDAQ:INBS) reported quarterly losses of $(0.36) per share. The company reported $843.884 thousand in sales this quarter. This is a 15.95 percent increase over sales of $727.824 thousand the
08-15 20:41
Intelligent Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue Growth and Increased Operational Efficiencies
Intelligent Bio Solutions Inc. reported a 16% revenue growth in Q4 2025, driven by increased demand for drug testing cartridges. The company advanced efforts to secure U.S. FDA 510(k) clearance for its opiate test system, aiming to expand beyond Forensic Use Only settings. Fiscal 2025 marked higher-margin cartridge sales and operational improvements, with a customer base exceeding 450 accounts across 24 countries. Expansion efforts continue in Ca...
08-15 12:30
Intelligent Bio Solutions to Participate in the Sidoti Micro-Cap Virtual Conference on August 20-21, 2025
Intelligent Bio Solutions Inc. announced that its management team will participate in the Sidoti Micro-Cap Virtual Conference on August 21, 2025, at 9:15 a.m. ET. The Company, which specializes in rapid, non-invasive drug testing solutions, will discuss its Intelligent Fingerprinting Drug Screening System, designed for workplace safety. To learn more or schedule a meeting, contact Sidoti or KCSA Strategic Communications. Visit http://www.ibs.inc ...
08-12 12:30
Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum
Intelligent Bio Solutions Inc. expects a 16% sequential and year-over-year revenue growth in its fiscal fourth quarter ended June 30, 2025, driven by higher-margin cartridge sales and account growth. The company submitted an FDA 510(k) application for its opiate test system, upgraded its drug screening system for global adoption, and launched localized websites and CRM enhancements in Europe, the Middle East, and Latin America. Preliminary result...
08-07 12:30
Intelligent Bio Solutions Submits Key FDA Information
Intelligent Bio Solutions ( ($INBS) ) has shared an announcement. On August 6, ...
08-06 21:50
